Find clinical trials

The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic) compared with placebo in pediatric and adult subjects (age 4-55 years) diagnosed with Lennox Gastaut Syndrome (LGS).

Study ALN-AGT01-008 (ZilebEsiraN CardIovascular OuTcome Study in Hypertension [ZENITH]) is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study designed to evaluate the efficacy and safety of zilebesiran, administered subcutaneously (SC), in adult patients with established CVD or high risk for CVD whose hypertension is not adequately controlled by at least 2 standard of care antihypertensive medications.  The primary objective of the study is to evaluate the efficacy of zilebesiran in patients with uncontrolled hypertension and with either established CVD or high risk for CVD by demonstrating the ability of zilebesiran to reduce the risk of CV death, nonfatal MI, nonfatal stroke, or HF events (hospitalization for HF or urgent HF visit). Secondary and exploratory objectives of the study include evaluating the effect of zilebesiran on additional clinical outcomes, blood pressure, and renal function.